EUVIMEDOpdag EUVIMED
Crossref

Use of Pembrolizumab in HIV-Associated Progressive Multifocal Leukoencephalopathy: A Four-Case Series

Clara Beatriz Palacios Morenilla

Journal of Innovative Clinical Trials and Case Reports · 2026-03-01 · 2 (2) · 1-5

DOI: 10.63721/26jctc0137 ↗

At a glance

Journal article in Journal of Innovative Clinical Trials and Case Reports, published online on 2026-03-01. Written by Clara Beatriz Palacios Morenilla.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Progressive multifocal leukoencephalopathy (PML) caused by JC virus (JCV) remains a severe opportunistic infection in people with advanced HIV infection. Combined antiretroviral therapy (cART) is the cornerstone of management, but prognosis remains poor in many cases and effective adjunctive therapies are lacking. Programmed death-1 (PD-1) blockade with pembrolizumab has emerged as a potential strategy to restore antiviral immune responses.

Methods

We conducted a retrospective case series of four adults with HIV-associated PML treated with pembrolizumab under compassionate use between January 2023 and May 2025 at a tertiary hospital in Spain. Diagnosis was established by compatible neurological and radiological findings together with detection of JCV-DNA in cerebrospinal fluid (CSF) by polymerase chain reaction. All patients received pembrolizumab (2 mg/kg every 3 weeks for at least one cycle) combined with bictegravir/emtricitabine/tenofovir alafenamide. Clinical, virological, immunological and safety data were collected.

Results

Four patients were included, three men and one woman, with a median age of 43 years (interquartile range [IQR] 25–56). Median baseline CD4+ T-cell count was 142 cells/µL (IQR 9–390), median plasma HIV viral load was 5.5 × 10^5 copies/mL, and median baseline NIHSS score was 3 (IQR 2–7). After pembrolizumab initiation, all patients showed neurological improvement, virological response, or both. Two patients experienced early neurological improvement, with NIHSS decreasing from 4 to 2 and from 3 to 1. In the other two patients, CSF JCV-PCR decreased from 5 × 10^5 copies/mL to undetectable and from 1 × 10^6 to 150 copies/mL, respectively, accompanied by parallel neurological improvement. Median CD4+ T-cell increase during early follow-up was +35 cells/µL (IQR 20–60). Treatment was well tolerated. No immune-related adverse events, infusion reactions, or vascular complications were observed. One patient developed a transient low-grade fever that resolved spontaneously without treatment interruption.

Conclusions

In this small case series, pembrolizumab combined with cART was feasible and well tolerated in patients with HIV-associated PML and was associated with virological and neurological improvement. These findings support further evaluation of PD-1 blockade as adjunctive therapy in selected cases of HIV-associated PML.

Cite

APA

Morenilla, C. B. P. (2026). Use of Pembrolizumab in HIV-Associated Progressive Multifocal Leukoencephalopathy: A Four-Case Series. Journal of Innovative Clinical Trials and Case Reports, 2(2), 1-5. https://doi.org/10.63721/26jctc0137

Vancouver

Morenilla CBP. Use of Pembrolizumab in HIV-Associated Progressive Multifocal Leukoencephalopathy: A Four-Case Series. Journal of Innovative Clinical Trials and Case Reports. 2026;2(2):1-5. doi:10.63721/26jctc0137

BibTeX
@article{Morenilla2026,
  author = {Morenilla, Clara Beatriz Palacios},
  title = {Use of Pembrolizumab in HIV-Associated Progressive Multifocal Leukoencephalopathy: A Four-Case Series},
  journal = {Journal of Innovative Clinical Trials and Case Reports},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {1--5},
  doi = {10.63721/26jctc0137}
}
Start for free →